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Summary
Objective: The functional integrity of articular cartilage is determined by a balance between chondrocyte biosynthesis of extracellular matrix
and its degradation. In osteoarthritis (OA), the balance is disturbed by an increase in matrix degradative enzymes and a decrease in
biosynthesis of constitutive extracellular matrix molecules, such as collagen type II and aggrecan. In this study, we examined the effects of
the sulfate salt of glucosamine (GS) on the mRNA and protein levels of the proteoglycan aggrecan and on the activity of matrix
metalloproteinase (MMP)-3 in cultured human OA articular chondrocytes.
Design: Freshly isolated chondrocytes were obtained from knee cartilage of patients with OA. Levels of aggrecan and MMP-3 were
determined in culture media by employing Western blots after incubation with GS at concentrations ranging from 0.2 to 200 µM. Zymography
(casein) was performed to confirm that effects observed at the protein level were reflected at the level of enzymatic activity. Northern
hybridizations were used to examine effects of GS on levels of aggrecan and MMP-3 mRNA. Glycosaminoglycan (GAG) assays were
performed on the cell layers to determine levels of cell-associated GAG component of proteoglycans.
Results: Treatment of OA chondrocytes with GS (1.0–150 µM) resulted in a dose-dependent increase in aggrecan core protein levels, which
reached 120% at 150 µM GS. These effects appeared to be due to increased expression of the corresponding gene as indicated by an
increase in aggrecan mRNA levels in response to GS. MMP-3 levels decreased (18–65%) as determined by Western blots. Reduction of
MMP-3 protein was accompanied by a parallel reduction in enzymatic activity. GS caused a dose-dependent increase (25–140%) in
cell-associated GAG content. Chondrocytes obtained from 40% of OA patients failed to respond to GS.
Conclusions: The results indicate that GS can stimulate mRNA and protein levels of aggrecan core protein and, at the same time, inhibit
production and enzymatic activity of matrix-degrading MMP-3 in chondrocytes from OA articular cartilage. These results provide a cogent
molecular mechanism to support clinical observations suggesting that GS may have a beneficial effect in the prevention of articular cartilage
loss in some patients with OA.
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Introduction
Osteoarthritis (OA) is a disease of diarthrodial joints
characterized by the progressive degradation and loss of
articular cartilage. OA affects more than 50 million people in
the United States, and its incidence increases with increas-
ing age1. There is no cure for this common disease, and the
currently used treatments modify only the symptoms of the
disease rather than the underlying process. Therefore,
development of therapies that modify the pathophysiology
of OA is essential. Recently, glucosamine sulfate (GS) has
received attention as a putative disease-modifying agent
for OA2,3, and numerous clinical and basic investigations
have been or are being conducted to examine the ability of
GS to relieve OA symptoms and to modify the disease
process3,4.
Cartilage comprises an extracellular matrix consisting
of proteoglycans (PGs), collagens (types II, IX, XI, and
others), and water5,6. Interaction between PGs and
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collagen provides unique structural and physiological prop-
erties for cartilage to function in weight bearing and joint
motion. Cartilage PGs consist of a protein core with glycos-
aminoglycan (GAG) side chains7. The GAGs in human
cartilage PGs include keratan sulfate, dermatan sulfate,
heparan sulfate, and chondroitin sulfate. They are com-
posed of repeating disaccharide units, which are combina-
tions of a hexuronic acid (D-glucuronic acid, L-iduronic
acid, or D-galactose) and hexosamine (D-glucosamine or
D-galactosamine). D-glucosamine is the hexosamine com-
ponent of keratan sulfate and heparan sulfate. These GAG
components impart high negative-charge density, known as
fixed-charge density, to PGs and, in turn, to the matrix. PG
have the ability to bind water and cations (Na+) to form a
resilient layer on the epiphyses of long bones that acts in
part to cushion and protect the joint and provide cartilage its
characteristic resistance to mechanical stress. Loss of this
protective layer leads to roughening and fissuring of the
cartilage and can eventually result in complete erosion to
subchondral bone. Healthy cartilage maintains a dynamic
equilibrium between processes that produce and pro-
cesses that degrade the matrix components8. It is thought
that in OA, this equilibrium is disturbed, and matrix compo-
nent degradative processes dominate, leading to increased
loss of matrix.
Glucosamine (2-amino-2-deoxy-D-glucose) is one of the
two hexosamine sugars. The rationale for using glu-
cosamine for the treatment of OA stems from the metabolic
pathway of GAG production and proteoglycan (PG) assem-
bly. Glucosamine in the form of glucosamine 6-phosphate
is the basic building block required for the biosynthesis of
GAGs and, ultimately, the formation of functional PGs. The
putative ability of glucosamine in halting or reversing
joint degeneration may be due to its participation as essen-
tial substrate for the biosynthesis of the GAG used for
the formation of PGs. Glucosamine is also a crucial com-
ponent of the biosynthetic pathway of hyaluronic acid, a
molecule that provides the backbone for assembly of
several PG molecules to form the large PG aggregates
characteristic of normal articular cartilage. Recent studies
using 13C-glucosamine in a cartilage explant culture model
have demonstrated a preferential incorporation of glucos-
amine into the galactosamine moieties of chondroitin
sulfate9.
Some recent studies have demonstrated the effect of
glucosamine at a molecular level in a number of
chondrocyte-culture systems10–14. Glucosamine is capable
of stimulating PG synthesis11, inhibiting the degradation of
PGs12, and stimulating the regeneration of cartilage in
vivo15,16. There is also evidence that glucosamine can
affect the biosynthesis of PGs as demonstrated by an
increase in the incorporation of radiolabeled sulfur into
glucosamine-treated cartilage in vitro11. Several clinical
trials have reported some therapeutic effects when oral
glucosamine was administered to patients with OA2,3.
Evidence from these trials suggests that glucosamine may
provide pain relief, reduced tenderness, and improved joint
mobility. Furthermore, some studies have suggested that
GS may have a chondroprotective effect in patients with
OA3. The results we report in this article demonstrate that
GS stimulates aggrecan mRNA and protein levels and
reduces matrix metalloproteinase (MMP)-3 protein and
enzymatic activity in cultured human OA articular chondro-
cytes and, therefore, indicate that GS may arrest the
progression of articular cartilage degradation and, at
the same time, stimulate production of new cartilage
macromolecules.
Methods
CELL CULTURE
Tissue from adult knee cartilage discarded during arthro-
plastic surgery was obtained from patients with OA. Tissue
was obtained and utilized following institutional review
board-approved protocols. The average age of the patients
from whom tissue was procured was 72 years (range,
58–80 years) and was evenly distributed between males
and females; no further demographics were obtained.
Chondrocytes were isolated from the articular cartilage of
tibial plateaus and femoral chondyles of tissue procured
within 6 h of surgery and processed as previously de-
scribed for isolating chondrocytes from epiphyseal carti-
lage17. Briefly, chondrocytes were isolated from pooled
femoral and tibial cartilage from individual patients by an
initial 1 h incubation with 1 mg/ml each of trypsin and
bacterial collagenase (Worthington Biochemicals Co.,
Freehold, NJ) followed by an overnight digestion in
0.5 mg/ml bacterial collagenase. The following morning,
the isolated chondrocytes were washed three times in
Dulbecco’s modified Eagle’s medium (DMEM), counted,
and plated in suspension cultures at 5–10×106
chondrocytes/60 mm poly-(2-hydroxyethyl methacrylate)-
coated culture dishes. Under these conditions, the
cartilage-specific phenotype is preserved for ≥6 months in
culture17. Cultures were maintained in DMEM supple-
mented with 10% fetal bovine serum, 1% vitamin solution
(GIBCO, Grand Island, NY), 2 mM L-glutamine, 100 U/ml
penicillin, 100 µg/ml streptomycin, 2.5 µg/ml amphotericin
B, and 50 µg/ml ascorbic acid. A 25 mM stock of GS (the
sulfate salt of glucosamine, glucosamine SO3H; provided
by Rotta Research Laboratorium, Monza, Italy) was pre-
pared in distilled/de-ionized H20 and diluted in DMEM to
the appropriate concentrations. The chondrocytes were
cultured for 24 h without GS. GS was then added on the
second day of culture and every 3 days thereafter. In
experiments designed to assess the ability of GS to modify
chondrocyte metabolism under the stimulatory effect of
interleukin (IL-1β), chondrocyte suspension cultures were
established as described earlier, and human recombinant
IL-1β (Catalog number 1457756, Roche, Indianapolis, IN)
was included at 5 ng/ml for the same incubation period with
GS. The concentration of 5 ng/ml was used based on our
previous studies18. Samples for analysis were harvested
following 72-h incubation with GS or under control condi-
tions. The medium was collected and stored frozen with
protease inhibitors, and the cell layer was either extracted
for RNA analysis as subsequently described or, in some
experiments, analyzed for levels of various proteins. In
these cases, the cells (and associated matrix) were col-
lected by the addition of a lysis buffer consisting of 0.1 M
NaCl and 0.5% Triton-X with proteinase inhibitors.
RNA EXTRACTION
RNA was extracted from cultured chondrocytes (which
were harvested by washing with cold Hank’s balanced
salt solution) by lysis with Trizol (BRL Life Technologies,
Gaithersburg, MD). The concentration of RNA was deter-
mined by OD260, and its integrity was evaluated by the
electrophoretic mobility of 28S and 18S ribosomal RNA in
agarose gels containing ethidium bromide. Northern blots
were prepared following the electrophoresis of 10 µg of
total RNA in denaturing 0.8% agarose gels. Prior to trans-
blotting (by capillary blotting) onto nylon membranes
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(Roche), the gels were soaked successively in 0.5 M
NaOH, 50 mM Tris, and 10× standard saline citrate (SSC)
twice for 15 min.
Probes were prepared by [α-32P]dCTP (Amersham,
Piscataway, NJ) random primed labeling of cDNA inserts
(Ready-To-Go labeling mix beads, Pharmacia, Summit,
NJ). Prehybridization and hybridization were performed at
65°C for 30 and 90 min, respectively, using a Quick-Hybe
(Amersham) hybridization buffer. Northern blots were
washed three times for 20 min at 55°C with 0.5×, 0.25×,
0.1× SSC, and 0.1% sodium dodecylsulfate (SDS). The
membranes were exposed to radiographic film for 6–24 h
at −70°C. The resulting images were quantified using
computer-integrated densitometry. Variations in gel loading
were corrected by densitometric measurement of the ribo-
somal bands in photographic negatives of the ethidium-
stained gels.
SDS-POLYACRYLAMIDE GEL ELECTROPHORESIS AND WESTERN
BLOT ANALYSIS
When each culture was harvested, the culture media
were precipitated with 9 volumes of ethanol (at −70°C for
≥30 min), and, following centrifugation (l0 min at 12 000×g),
the resultant pellet was dissolved in SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) sample buffer containing
5 mM ethylenediamine tetraacetic acid (EDTA). Prior to
loading, all samples were heated to 75–80°C for 10 min.
Mini-gel electrophoresis and Western blots were prepared
and analyzed by standard protocols, as previously de-
scribed19, using 6.5% polyacrylamide gels containing 5 mM
EDTA. Transfer of proteins to supported nitrocellulose was
carried out using methanol-free transfer buffer containing
25 mM Tris and 192 mM glycine, with a pH of 8.3. Western
blots were performed as previously described with the
exception that the post-transfer membranes were sequen-
tially blocked with 10% non-fat milk in phosphate-buffered
saline (PBS) for 1.5 h and 5% bovine serum albumin (BSA)
in PBS for 30 min. The method of detection was chemilu-
minescence based on horseradish peroxidase (HRP; ECL,
Amersham). All primary antibodies were monoclonal. The
anti-aggrecan monoclonal antibody (BE123) was kindly
provided by Dr Tibor Glant, Rush University Medical
School, and the anti-MMP-1 and anti-MMP-3 monoclonal
antibodies were purchased from Biosource International
(Camarillo, CA). A propeptide-specific anti-human collagen
type II antibody (SJ443) was generated and characterized
by our laboratory19. All primary antibodies were diluted to
1/1000 in 2.5% BSA in PBS with 0.1% nonidet and were
used more than once. The secondary antibody was an
HRP-labeled sheep anti-mouse or rabbit (i.e., for collagen
antibody) immunoglobulin (Roche), used at 1:8000 and
incubated for 60 min. Detection using the ECL chemilumi-
nescence reagents (Amersham) was performed as outlined
by the manufacturer, and exposure times were between 30
and 120 s.
Western blots for collagen were performed using
samples of media. An equal volume of each medium
sample was precipitated with 9 volumes of alcohol prior to
dissolving into sample buffer for SDS-PAGE.
ZYMOGRAPHY
For zymography, 1 µl of 100 µM p-aminophenyl mercuric
acetate (APMA) was added to 100 µl aliquot of culture
media and incubated at 37°C for 30 min. Matching samples
were prepared without APMA activation. Proteins in all
samples were precipitated in a 2× volume of acetone
followed by cooling at −70°C for 1 h. The samples were
centrifuged (12 000×g, 30 min, 4°C), and the pellets were
dried in a vacuum centrifuge. The pellets were resus-
pended in water, an aliquot was mixed 1:1 with a loading
buffer (0.125 M Tris–HCl (pH 6.8), 20% glycerol, 4% SDS,
0.05% bromophenol Blue), and they were incubated at
room temperature for 10 min. Aliquots were separated in
gels containing either 0.1% gelatin or 0.05% casein. The
gels were incubated in a renaturing buffer (2.5% Triton-X-
100) for 30 min at room temperature followed by another
30 min in a developing buffer (10 mM Tris base, 40 mM
Tris–HCl, 0.2 M NaCl, 5 mM CaCl2, 0.02% (w/v) Brij 35).
The gels were then incubated overnight at 37°C in fresh
developing buffer, stained with 0.05% Coomassie Blue
R250 for 30 min, destained for 15 min in 45% methanol/7%
acetic acid solution, and washed twice for 20 min in water
before drying. The gels were digitized, and cleared areas of
proteinase activity were quantitated.
GAG ASSAY
To determine whether GS had an effect on cell-
associated PGs and/or on PGs secreted into the media of
the suspension cultures, GAG assays were performed on
the clusters of chondrocytes (and their cell-associated
matrix) and the media from terminated cultures. Cultures of
chondrocytes were incubated with 0–400 µM GS as de-
scribed in the preceding discussion. In experiments in
which chondrocytes were not used for RNA isolation, they
were collected by centrifugation and lysed in a homogen-
ization buffer (1 M NaCl, 1.0% Triton X-100). The resultant
lysates were assayed prior to and after dialysis, and no
significant difference in the results was obtained. Routinely,
equal aliquots (100 µl) of the lysates or media were diluted
with an equal volume of water and were assayed for GAG
content using the dimethyl methylene blue dye-binding
assay kit (Blyscan) as described by the manufacturer
(BioScan, Belfast, Northern Ireland). For the purposes of
standardization, a DNA assay was performed on the cell
extracts, and the GAG assay results were normalized to the
DNA content in each culture20.
Results
EFFECTS OF GS ON PG PRODUCTION
To determine the effects of GS on the expression of
constitutive matrix and matrix-related proteins by OA articu-
lar cartilage chondrocytes, an in vitro suspension culture
that allows the maintenance of the cartilage-specific phe-
notype for long periods of time was utilized17. In these
experiments, isolated chondrocytes were cultured with vari-
ous concentrations of GS for 3 days to 2 weeks. Analyses
were performed on separate media samples from each
culture (never pooled). Equal aliquots (100 µl) of media
were collected from the cultures, and the amount of PG
was determined by Western blot following digestion with
chondroitinase-ABC and keratinase. Figure 1 is a repre-
sentative Western blot of the effects of GS on aggrecan
detected in culture media from chondrocytes from a 70-
year-old individual with OA. In this experiment, chondro-
cytes were incubated for 2 weeks with 0, 1.0, 5.0, 25, 100,
and 150 µM GS. The antibody used reacts with the chon-
droitin sulfate stubs that remain associated with the aggre-
can core protein. Because aggrecan is more than 250 kDa
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and is likely to contain large numbers of GAG side chains,
it is expected that even the lyase-digested PG appears
polydisperse in polyacrylamide gels. Figure 1(A) shows the
expected PG broad band migrating at the top of a 5% gel
above the 212 kDa molecular weight standard. Increasing
amounts of aggrecan protein can be detected in these
cultures in response to increasing doses of GS. Densito-
metric analysis of the aggrecan protein detected in this
Western blot is shown in Fig. 1(B), which demonstrates that
there is a dose-related increase from 30% at 1.0 µM to
120% at 150 µM GS. Each GS-treated culture was com-
pared with the untreated control to determine the percent
difference. This experiment is representative of six of the 10
separate patients studied (four of the cases did not respond
to any concentration of GS tested).
To confirm these findings, we assayed the cell layers and
media from chondrocyte cultures from the same patients
for GAG content using the dimethyl methylene blue dye-
binding assay. In Fig. 2, we show two separate and
representative experiments demonstrating that there was
an increase in cell-associated GAG content in the cultures
from chondrocytes treated with various concentrations of
GS. The increase showed a dose response and was at
least 50% greater at the concentrations of GS ranging from
25 to 400 µM compared with untreated controls. Little
change was observed in the soluble GAG (media) from
these cultures (data not shown). Collectively, the results in
Figs. 1(A, B) and 2(A, B) demonstrate that GS increases
the expression of aggrecan core protein and that this core
protein is post-translationally modified as expected by the
attachment of GAG chains.
EFFECTS OF GS ON TYPE II COLLAGEN PRODUCTION
In some cultures, we examined the effect of GS on
production of type II procollagen protein by Western blot.
As shown in this representative Western blot, there was
no measurable change in the levels of this cartilage colla-
gen detected using a propeptide collagen type II-specific
antibody (Fig. 3).
EFFECTS OF GS ON PG mRNA LEVELS
To ascertain whether the effect of GS on chondrocyte PG
biosynthesis was reflected at the level of mRNA, we
performed Northern hybridizations of total RNA from the
suspension cultures of OA cartilage-derived primary
chondrocytes. We examined 10 µg of total RNA from
chondrocytes treated for 72 h with 10–150 µM GS and
probed as described earlier in the ‘Methods’ section, with
aggrecan cDNA. In Fig. 4(A), we show a representative
Northern analysis for steady-state levels of aggrecan
mRNA. In this representative experiment, the chondrocytes
Fig. 1. Aggrecan Western blot. (A) Representative western blot
prepared from cultures of chondrocytes from a 70-year-old indi-
vidual with OA. Cells were cultured as described in ‘Methods’
section. Samples (100 µl) from the collection of media on day 14
(after the last 72 h with GS) were digested with chondroitinase-
ABC and separated on SDS-PAGE (5% gel). Chondrocytes were
treated for 2 weeks with 0, 1.0, 5.0, 25, 100, and 150 µM GS (lanes
1–6, respectively). Antibody BE123 was used at 1:1000 dilution,
which reacts with the chondroitin sulfate stubs that remain associ-
ated with the aggrecan core protein and, as shown, presents as a
polydisperse band in polyacrylamide gels. The characteristic band
is located at the top of the gel well above the 212 kDa molecular
weight standard. (B) Densitometric analysis of the aggrecan pro-
tein detected in this Western blot. The data are presented as a
percent of control where the control is the untreated culture.
Fig. 2. GAG assay. Culture media and cell lysates from 72-h
chondrocyte cultures, from the same patients, from whom samples
were analyzed for protein and mRNA, were subjected to a dimethyl
methylene blue dye-binding assay. Cell lysate (100 µl each) was
tested and the GAG content was determined from a standard
curve of known amounts of chondroitin sulfate. Each data point
was standardized to the µg of DNA in each lysate. The graphs
represent two separate experiments using chondrocytes obtained
from two different OA patients. The doses of GS tested range from
25 to 400 µM in panel A and from 0.02 to 200 µM in panel B. Each
chondrocyte culture treated with GS shows a greater level of GAG
per µg of DNA.
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were treated with 50 and 200 µM GS (lanes 3, 4) in
comparison with the levels present in untreated chondro-
cytes (lane 1). After densitometric analysis and standard-
ization using 28S ribosomal RNA, it can be clearly seen in
Fig. 4(B) that the levels of aggrecan mRNA are increased
by nearly threefold in response to the 72-h culture with GS
(patient 1). Similar results were obtained using chondro-
cytes from another patient (patient 2). For these analyses,
we used the stained ribosomal RNA (28S) for standardiz-
ation because this is more accurate than relying on ‘house-
keeping’ genes, such as GADPH or actin, that can be
altered in response to various cytokines or agents. When
Northern blots were incubated with MMP-3 cDNA, no
substantial changes in the level of MMP-3 mRNA were
observed. The data shown in Fig. 5 were obtained from a
representative Northern blot (of six separate experiments)
and were standardized using a probe to 7S RNA.
EFFECTS OF GS ON IL-1β-INDUCED CHANGES IN AGGRECAN mRNA
IL-1β is a cytokine that exerts profound effects on
chondrocyte metabolism and on extracellular matrix protein
and degradative enzyme gene expression. Therefore, we
examined the effect of GS on IL-1β-treated OA chondrocyte
cultures. In Fig. 4, it can be seen that IL-1β downregulated
the expression of aggrecan mRNA (lane 2) and that, when
IL-1β-treated cultures were treated with GS, there was a
reversal, albeit modest, of the IL-1β effects. As seen in this
representative Northern analysis, there was a reproducible
increase in the levels of aggrecan mRNA (lanes 5–7)
when compared with the levels present in chondrocytes
incubated with IL-1β alone.
EFFECTS OF GS ON EXPRESSION OF MMP-1 AND MMP-3
Because OA cartilage pathology is a result, in part, of an
imbalance of biosynthesis and degradation resulting in a
compromised cartilage structure and function, we per-
formed experiments to examine the effect of GS on MMP-1
and MMP-3 proteins and their activities. We also explored
the effects of GS on the expression of MMP-1 and MMP-3
in cultured OA chondrocytes inducted by IL-1β. In Fig. 6, we
demonstrate that GS at 1.0–150 µM for 72 h was capable
of decreasing the levels of pro-MMP-3 produced by
chondrocytes. We also found that there was a modest
reduction of the MMP-3 levels in IL-1β-treated chondro-
cytes (Fig. 7). In Western blots using secreted MMP
precipitated from the culture media of chondrocytes after
24 h treatment with IL-1β, plus various concentrations of
GS, it was shown that pro-enzyme levels were decreased
by the inclusion of GS in the culture. Figure 7 shows that in
IL-1β-treated cultures, MMP-3 levels decreased (18–65%)
in cultures treated with GS when compared with non-GS-
treated cultures. Levels of MMP-3 were affected to a
greater extent than those of MMP-1 (Fig. 8).
The reduction of MMP-3 protein was accompanied by a
parallel reduction in enzymatic activity after APMA acti-
vation in vitro, as determined by casein zymograms (Fig.
9). In these experiments, we tested the levels of MMP-3
enzymatic activity in media from cultures treated for 72 h
with or without GS. As shown in this representative casein
Fig. 3. Type II collagen protein assessment by Western blot. Media
collected from chondrocyte cultures treated with or without GS for
72 h were examined by Western blot for changes in production of
type II collagen protein. As shown in this representative Western
blot, there was no measurable change in the levels of type II
cartilage collagen detected using a pro-peptide-specific type II
collagen antibody. The GS concentrations tested in this repre-
sentative experiment were 0, 0.2, 1.0, 5.0, 25, 100, 150, 200 µM.
Each concentration is shown in lanes 1–8, respectively.
Fig. 4. Assessment of aggrecan mRNA steady-state levels by
Northern hybridizations. (A) Total RNA (10 µg) from chondrocyte
cultures treated with or without 5 ng/ml IL-1β and various concen-
trations of GS were analyzed. Shown here is a combined experi-
ment demonstrating the effects of GS alone at 50 and 200 µM
(lanes 3 and 4, respectively) on the levels of aggrecan mRNA as
compared with mRNA from control cultures (lane 1). The top panel
shows the characteristic band for aggrecan mRNA. For quantifi-
cation, the intensity of ribosomal RNA stained with ethidium
bromide (shown in the lower panel) was used. Lanes 2, 5–7 are
from samples treated with IL-1β at 5 ng/ml for 72 h with or without
GS. Lane 2 is from cultures treated with IL-1β alone, and lanes 5,
6, and 7 were from cultures treated with both IL-1β and GS at 50,
200, and 400 µM, respectively. (B) Graphic representations of the
data presented in lanes 1, 3, and 4 along with graphic represen-
tation of a separate experiment using chondrocytes from another
patient. Both graphs show a dose-dependant upregulation in the
steady-state mRNA levels for aggrecan.
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zymogram, a notable decrease in the levels of enzymatic
activity was observed in samples from cultures treated with
GS at concentrations of 25–150 µM. No active enzyme was
detected in these zymograms without activation.
Discussion
The search for potential chondroprotective agents is an
intensely pursued area of research with as many ap-
proaches as there are the aspects of OA pathogenesis
suitable for modulation. Numerous studies have described
a variety of agents that may be capable of modifying the
structural alterations occurring in articular cartilage during
the development of OA. One such putative chondroprotec-
tive agent that has generated a large amount of recent
attention is glucosamine, either as glucosamine-SO4 (GS)
or glucosamine-HCl. Glucosamine is a molecule that is an
example of an agent that was the subject of numerous
poorly controlled and anecdotal clinical studies before it
was studied in more rigorous basic science or controlled
clinical research studies. Although there is still substantial
controversy regarding the beneficial effects of glucosamine
Fig. 5. Assessment of MMP-3 mRNA steady-state levels by
Northern hybridizations. The effects of various GS concentrations
on the steady-state levels of MMP-3 mRNA were analyzed after a
72-h culture. Shown are data obtained from densitometric analysis
from a representative Northern hybridization (representative of six
separate experiments). The data are standardized to 7S ribosomal
RNA and expressed as pixel volume (PV). No substantial changes
in the level of MMP-3 mRNA were detected in response to 5.0, 25,
100, 150, 200 µM of GS when compared with no GS.
Fig. 6. MMP-3 protein assessment by Western blot. Equal volumes
of culture media from each chondrocyte culture were analyzed by
Western blots using MMP-3-specific antibodies. The level of pro-
MMP-3 detected decreases in a dose-dependant manner in
response to GS. Cultures were incubated for 72 h with 0, 1.0, 5.0,
25, 100, and 150 µM GS (lanes 1–6, respectively).
Fig. 7. MMP-3 protein assessment by Western blot in samples
cultured with IL-1β and GS. Samples from a different patient than
those from the patient shown in Fig. 6 were examined for the
effects of GS on the levels of active MMP-3 in cultures incubated in
the presence or absence of IL-1β. MMP-3 detected in media from
untreated control (lane 1) chondrocyte cultures and those that had
been treated for 72 h with IL-1β alone (lane 2), GS alone at 50 µM
(lane 3), or GS alone at 200 µM (lane 4) is shown. To ascertain
whether the MMP-3 expressed in cultures treated with IL-1β could
be downregulated, GS at 50, 200, and 400 µM was added to
cultures incubated with IL-1β at 5 ng/ml (lanes 5–7, respectively).
The results show that GS caused a modest reduction in IL-1β-
stimulated active MMP-3 levels.
Fig. 8. MMP-1 protein assessment by Western blot. Parallel
samples to the ones studied in Fig. 7 were prepared for Western
blot and probed with antibodies to MMP-1. The order of each lane
is identical to that of Fig. 7. It is clear that MMP-1 is not decreased
in the same manner as is MMP-3.
Fig. 9. Functional assay of MMP-3 activity by zymography. Cul-
tures were examined for the presence of MMP-3 by a functional
assay employing casein zymography. In this representative figure
(of six experiments), the media were activated with APMA, and
equal volumes of culture media were electrophoresed into casein
gels. Chondrocytes were incubated for 72 h without GS (lane 1) or
with 1.0, 5.0, 25, 100, 150 µM GS (lanes 2–6, respectively). Note
the reduction in MMP-3 activity induced by incubation with GS.
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in the treatment of OA2,4,21, several studies have provided
evidence suggestive of both symptomatic as well as chon-
droprotective effects3. The mechanisms responsible for
these putative beneficial effects of glucosamine have not
been completely elucidated to date. In this report, we
explored the effect of GS on the expression of molecules
representative of the biosynthetic and catabolic aspects of
articular cartilage. We studied aggrecan and the protease
MMP-3 that uses aggrecan as substrate as representative
paradigms of each of these pathways. The results of these
studies provide a biochemical and molecular foundation to
explain, at least in part, the recently described effects of
glucosamine in improving cartilage loss in patients with OA.
We employed an in vitro model of freshly isolated human
OA chondrocytes in a short-term suspension culture that
allows the preservation of the cartilage-specific phenotype.
We found that physiologically relevant doses of GS consist-
ently increased the levels of aggrecan core protein mRNA
from 30 to 120% when compared with untreated control
cultures.
We believe that these results are important because they
indicate that GS causes an increase in aggrecan gene
expression. Although it is possible that this increase results
from changes in aggrecan transcript stability, it is more
likely that it results from increased transcriptional activity of
the gene promoter. In this regard, several recent studies
have shown that components of the hexosamine pathway,
of which glucosamine is an important member, are capable
of potent modulation of the transcriptional activity of several
genes including those encoding fibronectin22 and plas-
minogen activator inhibitor-123 in glomerular mesangial and
endothelial cells, and leptin in adipocytes24. Furthermore, it
has been demonstrated that these effects appear to be
mediated by the transcription factor Sp123,25. Other studies
in support of these findings have demonstrated that hexos-
amines, including glucosamine, increased the activity of a
construct containing the Sp1 transcriptional activation
domain fused to a reporter gene DNA-binding domain23.
Notably, the human aggrecan gene promoter contains
several Sp1-binding sites that may be important in the
regulation of its expression26. Therefore, it is possible that
glucosamine-induced stimulation of aggrecan mRNA levels
observed in our studies may be the result of increased
transcriptional activity of the aggrecan gene promoter
mediated by Sp1. This putative mechanism is currently
being explored in our laboratories.
Critical to the functional integrity of aggrecan is the fact
that the core protein requires post-translational modifi-
cation with the covalent addition of GAG side chains. To
ascertain whether the aggrecan core protein molecule
contained GAG, we measured the level of GAG and
demonstrated that in parallel with the increase in core
protein mRNA, there was an increase in GAG content in
cultures treated with GS.
Collectively, the aggrecan mRNA data presented are
representative of results observed with chondrocyte
samples from separate patients. Whereas the data varied
from experiment to experiment in absolute amounts, the
results indicated that an increase in aggrecan biosynthesis
was observed in 60% of cases. The remaining 40% of
patients did not respond in the same manner to GS, failing
to show any differences from untreated control cultures.
The cartilage used in these studies was freshly obtained
from OA patients undergoing arthroplasty, and, because
the chondrocytes were studied within the first 3 days
following their isolation from the tissue, it would be ex-
pected that the cultures would closely parallel the in vivo
situation. This, for example, would presumably explain the
high baseline MMP levels detected in the cultures and
would also place emphasis on the importance of quantita-
tively small changes in a situation in which the chondro-
cytes have been already maximally stimulated in vivo.
Generally, the patients’ condition or therapy prior to surgery
was not known. However, we observed that one patient
whose chondrocytes consistently demonstrated the highest
response to GS was not taking any medication prior to
surgery. Moreover, this particular patient received neither
intraarticular steroid injections nor non-steroidal anti-
inflammatory medications for several weeks prior to
surgery.
The upregulation of the expression of a critical extra-
cellular matrix molecule such as aggrecan is likely to cause
a profound impact on the overall well-being of articular
cartilage, particularly if the degradative activities present in
the OA joint are favorably affected as well. In this regard,
we studied whether there was any effect of GS on the
expression of MMP-3, one of the proteases for which
aggrecan is a substrate. We examined the protein levels by
Western blot and demonstrated that the levels of pro-
enzyme were reduced by as much as 65% at the doses of
GS tested. In addition, we confirmed the effect of GS on
MMP activity by performing zymography, an assay that also
showed a parallel decrease in MMP-3 enzymatic activity. In
contrast with the ability of GS to reduce the levels of
MMP-3, no changes were observed in the levels of MMP-1
(data not shown). Even though the level and activity of
MMP-3 are high in OA cartilage and presumably also in the
OA chondrocytes used in these studies, we tested whether
IL-1β could further stimulate in vitro MMP-3 and evaluated
the effects of GS. As shown in the ‘Results’ section, we
found that the addition of GS to IL-1β-stimulated chondro-
cytes caused a reversal, albeit modest, of MMP-3 protein
levels detected by Western blot. Recently, it has been
shown that glucosamine inhibits the aggrecanase-
mediated response to IL-1β and retinoic acid, and, more-
over, that a similar effect is also attained with other
hexosamines27. Another study showed that glucosamine
reversed the decrease in PG synthesis and in UDP-
glucuronosyl-transferase I mRNA induced by IL-1β in rat
chondrocytes28. Further work by the same group sug-
gested that these effects may be due to both interference
by glucosamine of ligand binding to its cognate membrane
receptors as well as to inhibition of post-receptor signal-
ing29. Indeed, glucosamine has been shown to cause a
potent inhibition of activation of NFκβ, an important tran-
scription factor involved in many of the downstream effects
of the cytokine30. These observations suggest that in
addition to modifying the expression of aggrecan by affect-
ing the pool of building-block sugars for GAG, glucosamine
may exert a direct or indirect modulation effect on the
biosynthesis of the protease MMP-3. The mechanism for
this effect is not clearly established, although one mecha-
nism suggested is that glucosamine and other amino
sugars inhibit the production of glycosylphosphatidylinositol
(GPI)-linked proteins, which are necessary for the re-
sponse of chondrocytes to IL-1β31. Other studies have
shown that GS affects aggrecan biosynthesis by affecting a
reduction in protein kinase C and phospholipase A214.
The recent clinical human studies showing that glucos-
amine or GS are capable of modifying the symptoms of OA
and improving the cartilage alterations characteristic of the
disease may find biochemical support in the studies we
describe in this article. Our studies show that GS is capable
of acting on chondrocyte function in vitro. However, it has
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not been demonstrated whether similar effects can be
attained in vivo. For in vivo effects, it is required that
glucosamine of GS traverses the gut and reaches joint
tissues to have a direct effect on cartilage chondrocytes.
Although some earlier data have provided support for this
possibility, recent evidence using 13C-glucosamine in our
own laboratory conclusively demonstrated that ingested
glucosamine can be traced to articular cartilage where it
was found at high concentrations (unpublished obser-
vations). This study employed an animal model and the
administration of GS doses equivalent to those used in
humans. The results support the notion that one of the
mechanisms involved in the improvement of cartilage com-
position or characteristics caused by GS is through an
increase in the available glucosamine in relevant tissues
such as articular cartilage. Thus, results presented in this
article provide a cogent molecular mechanism to support
the clinical observations and the results of recent studies
suggesting that GS may have a beneficial effect on articular
cartilage chondrocytes by improving their biosynthetic
activity and preventing articular cartilage loss in some
patients with OA.
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